Chartwell Investment Partners LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 0.5% during the 2nd quarter, Holdings Channel reports. The firm owned 551,892 shares of the biopharmaceutical company’s stock after selling 2,528 shares during the period. Pfizer accounts for approximately 0.6% of Chartwell Investment Partners LLC’s investment portfolio, making the stock its 29th biggest holding. Chartwell Investment Partners LLC’s holdings in Pfizer were worth $20,023,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. W.G. Shaheen & Associates DBA Whitney & Co bought a new stake in Pfizer during the first quarter valued at $132,000. Braun Bostich & Associates Inc. bought a new stake in Pfizer during the first quarter valued at $139,000. Clearwater Capital Advisors LLC bought a new stake in Pfizer during the first quarter valued at $156,000. Goodwin Daniel L bought a new stake in Pfizer during the second quarter valued at $171,000. Finally, Bristol John W & Co. Inc. NY bought a new stake in Pfizer during the first quarter valued at $186,000. 69.08% of the stock is currently owned by institutional investors.

Shares of NYSE PFE opened at $43.52 on Wednesday. Pfizer Inc. has a 1-year low of $33.20 and a 1-year high of $45.81. The stock has a market cap of $263.59 billion, a PE ratio of 16.42, a P/E/G ratio of 2.23 and a beta of 0.88. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The firm had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. During the same quarter in the prior year, the business earned $0.67 earnings per share. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 3 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be issued a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.13%. Pfizer’s dividend payout ratio is presently 51.32%.

In other Pfizer news, major shareholder Pfizer Inc bought 55,556 shares of the stock in a transaction that occurred on Monday, October 15th. The shares were bought at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the acquisition, the insider now directly owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

PFE has been the topic of a number of research analyst reports. Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, October 4th. Morgan Stanley set a $45.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, August 29th. Credit Suisse Group upped their price target on shares of Pfizer from $39.00 to $40.00 and gave the company a “neutral” rating in a research report on Wednesday, August 1st. Bank of America upped their price target on shares of Pfizer from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, August 1st. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $45.00 price target on shares of Pfizer in a research report on Tuesday, October 30th. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $42.67.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/11/14/chartwell-investment-partners-llc-has-20-02-million-position-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Story: Ex-Dividend

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.